Date: 2011-02-02
Type of information:
phase: 3
Announcement: discontinued study
Company: Antisoma (UK)
Product: AS1413 (amonafide)
Action mechanism: inhibitor of topoisomerase II and DNA intercalating agent
Disease: high-grade brain tumors
Therapeutic area: Cancer Oncology
Country:
Trial details:
Latest news: Antisoma announced that the ACCEDE phase III trial of AS1413 (amonafide) in secondary acute myeloid leukaemia (secondary AML) did not meet its primary endpoint. Development of AS1413 will be discontinued.
